A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)
Status:
NOT_YET_RECRUITING
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
For Phase 1, researchers will explore the safety, and tolerability of PMS-101 and determine the recommended Phase 2 dose (RP2D) using the donor site.
For Phase 2a, researchers will compare PMS-101 to a standard-of-care to see if PMS-101 works to treat mid-dermal burns.